美沙拉嗪联合益生菌治疗炎症性肠病疗效分析.docVIP

美沙拉嗪联合益生菌治疗炎症性肠病疗效分析 　　[摘要] 目的 探讨美沙拉嗪联合益生菌治疗炎症性肠病的临床疗效。方法 从该院2013年1月―2014年1月收治的炎症性肠病患者中随机性抽取92例作为研究对象，并将其分为研究组和对照组，每组46例。研究组患者给予美沙拉嗪联合益生菌治疗，对照组给予美沙拉嗪治疗，比较两组患者治疗效果和不良反应发生率。结果 治疗后研究组治疗总有效率为95.65%，明显高于对照组的78.26%，两组数据比较差异有统计学意义（P0.05）；研究组的不良反应发生率为10.87%，明显低于对照组的23.91%，组间数据比较差异有统计学意义（P0.05）。 结论 美沙拉嗪联合益生菌在炎症性肠病患者中疗效显著，可以显著提高患者治愈率和减少不良反应，具有安全、可靠等优点，值得临床推广和应用。 　　[关键词] 美沙拉嗪；益生菌；炎症性肠病；临床疗效 　　[中图分类号] R71 [文献标识码] A [文章编号] 1674-0742（2015）05（c）-0090-02 　　[Abstract] Objective To probe into the clinical effects of mesalazin enteric-coated combined with probiotics for inflammatory bowel disease. Methods 92 patients who suffered from the inflammatory bowel disease and who accepted treatments in our hospital from January， 2013 to January， 2014 were taken as the research objects， and these patients were randomly divided into the control group and the study group， with 46 patients in each group. In the study group， they were treated with mesalazin enteric-coated， while in the control group， they were treated with mesalazin Enteric-coated. Then， the curing effects and adverse reactions of these two groups of patients were compared. Results After the treatment， the response rate in the study group was 95.65%，which was evidently better than that in the control group， 78.26%，and the data of two groups has evidently differences while the differences had the statistical significance （P0.05）.Then， the incidence of adverse reaction in the study group was 10.87%，which was obviously lower than that in the control group， 23.91%， the differences had the statistical significance （P0.05）.Conclusion The clinical effects of inflammatory bowel disease cured by mesalazin enteric-coated combined with probiotics are good enough， which can evidently improve the cure rate of patients and reduce adverse reaction， in addition， it has advantages of safety， reliability and etc. Thus it should be promoted in the clinical application. 　　[Key words] Mesalazin Enteric-coated； Probiotics； Inflammatory bowel dis